OTC · IRBS
IR Biosciences Holdings Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 12:41 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 128.12K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 110.08K
- Avg. volume
- 53.37K
Price performance
IRBS price history
1M range · 0 trading sessions · Daily adjusted prices
IRBS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IRBS news
The latest Smart Investors Daily articles mentioning IRBS.
Stock researchCompany · Overview
IRBS research
Overview
Company profile and research snapshot.
Company profile
IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
